Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Paullee - thanks for the info.
First time I have seen these details from this co.
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc.
http://stonegateinc.com/reports/BPTH%20DEC%202019.pdf
Our market cap now equals cash on hand.
The market is not giving us any premium for the value of our technology.
If this valuation continues in 6 months our PPS will equal $6.50 and $5.00 in a year as our cash decreases.
I suspect no real valuation based on our technology until a partnership or drug approval.
Stocktwits shows this stock now has a large public following which it never had in the past.
If PN gets a partner or FDA approval of any drug the PPS like Alice is "going the Moon."
From Fidelity, yes thing are looking up for them. About time.
On December 4, 2019 Zacks Investment Research, Inc. upgraded BIO PATH HOLDINGS INC (BPTH) from HOLD to BUY.
Don’t know... I just buy the breakout
Why the big move? No news that I see.
Thanks SJ, I think we were just way too early to the party. If I was younger I might pick up some, but at this stage what I have will have to do . Will sell some for tax loss , at least I will get some benefit . Sure would be nice if they could get some licenses done .
Too, I suspect the positive numbers of 50% were not enough.
It is way to small a sample to draw any conclusions except for safety. Remember what happened last time!
The real news is again....NO SIDE EFFECTS!
If BPTH drops below $5 I may begin to buy again.
SJ, any idea why the results are viewed as negative, or I was thinking that they look to me like they are shot gunning without being able to complete a trial anywhere close to prediction.
Raising money before the results were announced is beginning to look like a stroke of genius.
The safety results are disappointing to the market so far.
Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia
GlobeNewswire GlobeNewswire•November 26, 2019
Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results
HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the successful completion of the safety testing of prexigebersen in combination with decitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients in Stage 2 of the Phase 2 clinical study. The safety segment of Stage 2 of the Phase 2 clinical trial comprised six evaluable patients who were treated with the combination of prexigebersen and decitabine.
“We are especially pleased to have successfully completed this key safety segment of our Phase 2 study as it allows us to move forward to the next segment of this important clinical study, which is the final, efficacy portion of Stage 2 of the Phase 2 study,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We are in the process of completing the documentation to submit for final approval of this last portion of Stage 2 of the Phase 2 study. These results are encouraging and give us greater confidence in the successful development of this very promising combination therapy for AML and MDS patients."
Although the treatment combination of prexigebersen and decitabine is not the treatment planned for the efficacy evaluation of Stage 2 of the Phase 2 clinical trial, the efficacy profile in this safety segment of the study was encouraging with 50% of patients having a response, including two patients (33%) showing complete responses with incomplete hematologic recovery and one patient (17%) showing partial response. For reference, in this class of AML and MDS patients, the complete response rate to treatment with decitabine alone is approximately 20%. Some patients are continuing to receive treatment.
As previously reported, Stage 1 of the Phase 2 clinical trial, which treated de novo AML patients with a combination of low dose cytarabine (LDAC) and prexigebersen, demonstrated similar safety results and efficacy compared favorably to treatment of this class of patients with LDAC alone. We believe that prexigebersen with its promising efficacy and safety profile, has the potential to be an ideal combination candidate with frontline therapy. The recent approval of the frontline therapy venetoclax provided an opportunity for adding prexigebersen to the combination of venetoclax and decitabine for the treatment of AML and MDS patients. The first step in this process was establishing the safety of combining prexigebersen and decitabine prior to proceeding to a combination treatment of prexigebersen, decitabine and venetoclax.
Bio-Path’s amended Stage 2 of the Phase 2 clinical trial will have two cohorts of patients. The first cohort will include untreated AML patients as existed in the pre-amended trial but with the addition of untreated high risk MDS patients, and a second cohort will include refractory/relapsed AML patients and high risk MDS patients. Both cohorts of patients will be treated with the combination of prexigebersen, decitabine and venetoclax. The Company is finalizing amendments to add this combination treatment to Stage 2 of the Phase 2 clinical trial.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for the treatment of blood cancers and is in the process of filing an IND for a Phase 1 clinical trial for solid tumors. The Company’s second product BP1002, which targets the Bcl-2 protein, will be evaluated for the treatment of lymphoma and solid tumors. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2020.
"Item 1.01 Entry Into a Material Definitive Agreement.
On November 21, 2019, Bio-Path Holdings, Inc. (the “Company”) and several institutional investors entered into securities purchase agreements (the “Purchase Agreements”), pursuant to which the Company agreed to sell, in a registered direct offering (the “Registered Direct Offering”), an aggregate of 808,080 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), and warrants to purchase up to 606,060 shares of Common Stock (the “Investor Warrants”) for a purchase price of $9.90 per Share and accompanying Investor Warrant and gross proceeds of approximately $8.0 million. Subject to certain ownership limitations, the Investor Warrants will be exercisable immediately upon issuance, have a term of five years from issuance and have an exercise price of $9.90 per share. The number of shares issuable upon exercise of the Investor Warrants and the exercise price of the Investor Warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.
On November 20, 2019, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to serve as the exclusive placement agent for the Company, on a reasonable best efforts basis, in connection with the Registered Direct Offering. The Company has agreed to pay the Placement Agent an aggregate cash fee equal to 7.0% of the gross proceeds received in the Registered Direct Offering. In addition, the Company has agreed to grant to the Placement Agent warrants to purchase up to 48,485 shares of Common Stock (the “Placement Agent Warrants”). The Placement Agent Warrants will be substantially on the same terms as the Investor Warrants, except that the Placement Agent Warrants will have an exercise price of $12.375 per share and will have a term of five years from the effective date of the Registered Direct Offering. The Company will also reimburse the Placement Agent $85,000 for non-accountable expenses and $10,000 for clearing expenses.
The Shares, Investor Warrants, Placement Agent Warrants and the shares issuable upon exercise of the Investor Warrants and Placement Agent Warrants will be issued pursuant to a prospectus supplement dated as of November 21, 2019, which was filed with the Securities and Exchange Commission in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-231537), which became effective on June 5, 2019, and the base prospectus dated as of June 5, 2019 contained in such registration statement.
The net proceeds to the Company from the Registered Direct Offering, after deducting the Placement Agent’s fees and expenses and the Company’s estimated offering expenses, and excluding the proceeds, if any, from the exercise of the Investor Warrants and the Placement Agent Warrants, are expected to be approximately $7.3 million. The Registered Direct Offering is expected to close on or about November 25, 2019, subject to the satisfaction of customary closing conditions. The Company currently intends to use these net proceeds for working capital and general corporate purposes.
The legal opinion of Winstead PC relating to the legality of the issuance and sale of the Shares, Investor Warrants, Placement Agent Warrants and the shares issuable upon exercise of the Investor Warrants and Placement Agent Warrants in the Registered Direct Offering is attached as Exhibit 5.1 to this Current Report on Form 8-K.
The description of terms and conditions of the Engagement Letter, the form of Purchase Agreement, the form of Investor Warrant and the form of Placement Agent Warrant set forth herein do not purport to be complete and are qualified in their entirety by the full text of the Engagement Letter, the form of Purchase Agreement and the form of Placement Agent Warrant, which are attached hereto as Exhibits 99.1, 10.1, 4.1 and 4.2, respectively."
The deal is at almost $10 per share. The warrants are the same price and exercisable immediately. This agreement could raise roughly $12 million for the company. A good decision by PN. He now has locked up funding for 3 years. This is plenty of time to prove at least one drug works and find a partner.
BPTH is not yet a buy for me but certainly a hold.
* * $BPTH Video Chart 11-21-2019 * *
Link to Video - click here to watch the technical chart video
You may question the timing but the raising the cash NOW is good idea. The problem is they waited too long so more dilution occurred.
QUOTES AS OF 01:32:33 PM ET 11/21/2019
Shares of Bio-Path Holdings Inc.(BPTH) are trading lower Thursday afternoon after the company announced a registered direct offering of 808,080 common shares and warrants to purchase another 606,060 common shares.
The company said "several health care-focused institutional investors" were taking part in the offering, which is expected to raise about $8 million.
At 12:53 p.m. EST, Bio-Path(BPTH) shares traded 17.04% lower at $8.12 per share. Volume topped 1.3 million shares, above the 65-day average volume of 59,583. Bio-Path(BPTH) has a market cap of $28.26 million, 2.83 million shares outstanding and a public float of 2.85 million.
Earlier in the session, shares touched as high as $11.78 after the company reported the Food and Drug Administration cleared its Investigational New Drug application for BP1002, intended for the treatment of lymphoma.
SJ was right. He usually is unfortunately. How disappointing-my take is nothing big coming anytime soon or why do this at this price:(
I just got some high 11's on pullback from 15's
BPTH
BPTH $13.00
from 15.74
Here is the earnings call transcript.
https://seekingalpha.com/article/4307110-bio-path-holdings-inc-bpth-ceo-peter-nielsen-q3-2019-results-earnings-call-transcript?page=5
There is an error in the transcript on page 5.
"And of course we have a systemic treatment that has shown the ability to penetrate the trauma in the pancreatic tumor and we are told by the investigators that this is the only thing they have seen that can do that. So we are really excited about that."
It should read "penetrate the stroma in the pancreatic tumor and we are told by the investigators that this is the only thing they have seen that can do that. So we are really excited about that."
A big deal IMO and perhaps a GAME CHANGER for BPTH.
Regarding PN's earnings call the information he now provides is excellent. I am excited about BP1003's status as the only drug with the ability to penetrate the stroma of a pancreatic cancer tumor. If this result holds up patient trials I see BP1003 as a game changer drug for this company.
I wish he would provide us with more information on this subject.
PN says cash will be needed at some time in the future via partnerships. $10 to $15 million should cover expenses until then.
There is no drug in a position for a partnership at this time. I do not believe we will have completed even a 19 patient cohort in any drug by the end of 2020. We need cash now as the burn rate is $2.2 million per quarter before ramping up additional drug trials. By then we will have $5 to $6 million in cash at best.
IMO the market decline of 10% today reflects disappointment at the lack of progress. This company's has many times in the past failed to meet timelines. I wait for that history to change. I would be ecstatic if they accelerated the efforts in all 3 drugs. Raising more cash would give the company financial security to proceed as they pleased. At 9 bucks a share the sale of 1 million shares nets 9 million in cash buying us an extra year to have drug trials in all 3 drugs well under way.
Let us hope are not raising money again at a buck a share. Why as a CEO would you take that risk?
Hard to tell if PN is excited because he is relatively monotone, but I have been listening to CCs for years and I have never heard him go on and on like this. Maybe a lot really is happening with this stock finally. He stated that the company is very well capitalized to do what it needs to do going forward. That I hope means we will not raise money anytime soon and especially at this level. Finally BPTH’s drug is the only thing that will penetrate pancreatic cancer. Most pancreatic cancer is a death sentence-anything that would help treat this would be huge! Could file IND in solid tumors next month.
Thanks for the sharing. I was very interesting to the BPTH, but the managements of the company seems too fool to make the products to the market
no posts for several weeks now.Has everyone finally woken up and running for the hills. it's nothing more than his private piggy bank
This one should slowly go up before the data is released in December.
Sure hope you are correct !
Something unlike recent run ups is in the works. This new board member will result in partnerships by year end. And PN is looking for an exit strategy that will not result in him working as the head of BPTH for the foreseeable future IMHO
That’s quite a few that have just Walked Off over the last 5 years! Hmmm......
Houston-based Bio-Path Holdings Inc. (Nasdaq: BPTH) has avoided being delisted from the Nasdaq Stock Market during a change on its board of directors.
Bio-Path, an oncology-focused biotech firm developing DNA therapeutics for cancer cells, announced that Mark Colonnese resigned as a member of the board of directors and all company committees on Oct. 10, according to an Oct. 15 filing with the U.S. Securities and Exchange Commission. Colonnese's resignation was not due to disagreement with the company on matters relating to Bio-Path's operations, policies or practices, per the filing.
However, Colonnese's resignation meant that Bio-Path was not in compliance with the Nasdaq stock exchange's continued listing requirements because the number of independent directors on the biotech firm's board, audit committee and compensation committee fell below the majority threshold.
To remedy that, Bio-Path appointed Martina Molsbergen, CEO of Malvern, Pennsylvania-based life sciences consultancy C14 Consulting, to its board as an independent director effective Oct. 11, per the filing.
“We are delighted to welcome Martina to our board of directors. Her considerable experience in business development will be invaluable as we seek a variety of partnerships and collaborations in order to advance our DNAbilize platform technology,” Peter Nielsen, president and CEO of Bio-Path Holdings, said in an Oct. 15 press release. “We thank Mark Colonnese for his considerable contributions to the board over the last two years and wish him continued success in his endeavors.”
After closing at $11.15 a share Oct. 15, Bio-Path Holdings' stock was trading down 1.43 percent to around $11 a share around midday Oct. 16, according to Yahoo Finance.
Bio-Path is a clinical- and preclinical-stage oncology company. The company's therapeutics drug candidates are in various stages of the development pipeline — from preclinical development up to Phase 2 clinical trials, according to the company's latest annual report. Products using Bio-Path's drug delivery and antisense technology, DNAbilize, are available for out-licensing or partnering.
In 2016, Bio-Path collaborated with Thomas Jefferson University in Philadelphia to target brain cancer with its DNAbilize technology.
Bio-Path was established in 2007. The company licensed technology and targets from the University of Texas M.D. Anderson Cancer Center, per the annual report. Bio-Path Holdings is headquartered at 4710 Bellaire Blvd.
Just bought some 11‘s
I spent way too much time detailing this for everyone in the past. He has taken millions of dollars out of this company while driving it into the ground. He has been way over his head and does not have the expertise to see it through. However, PN has manipulated things so that the shareholders can't vote him out. The only hope for this company at this point is that his age will catch up with him and he will finally retire. Unfortunately, I think those who are vocal, like myself, just enrage him and make him want to stay with the company even more. A competent CEO/COB would have had some of these studies done already, with product in the market. Yet, here we are, floundering. I don't even have hardly any shares anymore because of his tricks to dilute the angry shareholders.
<< IMO this company has been the personal PIGGY BANK for Peter Nielsen. >>
Unfortunately, that is the case with MANY penny stocks.
I am new to this message board, but I've been a share holder of BPTH for just under 4 yrs. now. In following this 'Message Board' it has helped me understand the history of this company. I have felt the disappointments & losses of this stock like most. I read the following article on Yahoo/Finance about BPTH's CEO a few days ago. IMO this company has been the personal PIGGY BANK for Peter Nielsen. One can only HOPE that this Science out performs the actions and mismanagement of the CEO.
https://finance.yahoo.com/quote/BPTH/history?p=BPTH
I am new to this message board, but I've been a share holder of BPTH for just under 4 yrs. now. In following this 'Message Board' it has helped me understand the history of this company. I have felt the disappointments & losses of this stock like most. I read the following article on Yahoo/Finance about BPTH's CEO a few days ago. IMO this company has been the personal PIGGY BANK for Peter Nielsen. Mid July BPTH was $17.50 ps, one can only HOPE that this Science out performs the actions and mismanagement of the CEO.
https://finance.yahoo.com/quote/BPTH/history?p=BPTH
The spread opens at $8.56 bid to $9.25 ask. That is unreal.
Wow!!
The recent PPS drop has been substantial.
Was the rise to $70 simply to set up a short play?
If so, I suspect we will see two dollars before $20.
Our analysts stock price predictions for some reason seem to herald price declines rather than their projected valuations. $28 a share seems like a long time ago.
I hope the company raised some money before the stock entered the single digits. If not, the dilution will be substantial when they need cash.
BPTH is good a stock, but you want a life changing ticker then come join me on UN*RG MMJ REIT Fund is taking over the ticker on Friday, this is the next II*PR which trades on 80 plus range now over 1 billion in market cap, but UN*RG will be the junior competition in the field. This can quickly go to $5.00 by Thanks Giving.
Hello single digits!
I hope the company does a deal for cash soon. Perhaps the deal is done and the buyer is dressing the price?
I disagree. PN gives quite a bit of new technical information. The delivery is poor but well worth the time to listen.
I believe we need to add cash now so we have 3 years of operational cash. I suspect it will take at least that long for FDA approval.
Not much new in the webcast. I note the burn rate is $2M per quarter with $17.1M cash in hand at end of June. With a bit of luck (and a lot of good management) we'll get results to send this stock up like a rocket before we need more cash.
http://wsw.com/webcast/hcw5/bpth/index.aspx
Looking to to enter later this week. Lets go BPTH
This news must be the catalyst for the late afternoon surge.
"Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference
GLOBENEWSWIRE 1:01 PM ET 9/3/2019
Symbol Last Price Change
BPTH 11.18up +0.07 (+0.63%)
QUOTES AS OF 04:00:00 PM ET 09/03/2019
HOUSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc.(BPTH), , a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 3:25 p.m. ET in New York.
A live webcast of the presentation can be accessed under “Events” in the Media section of the Company’s website at www.biopathholdings.com."
Let us hope they raise another 10 million before this stock hits single digits.
SJ , agree they should get the $=while they can. I see a few companies and invested in one that is further ahead in Pancreatic than Bpth and still many years out. I will admit I am not knowledgeable about the science and the trial process , but I have learned that when Bpth gives a timeline I need to at least double that. I too have only about 35% of original invested ( in a Roth)and don’t plan to add another penny. It should be sufficient if and when it ever hits. I will be too old to enjoy it unfortunately. Hope you folks are younger than me. Have a nice weekend !
Followers
|
101
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6389
|
Created
|
03/26/13
|
Type
|
Free
|
Moderators |
The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.
Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive.
A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson.
Patent protection for manufacturing their neutral lipid delivery system has been granted.
http://www.biopathholdings.com
This link to the company website describes their delivery technology:
http://biopathholdings.com/technology/
The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 2+ million in cash. BIO-PATH'S viability is in question due to a lack of funds.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |